MedinCell, headquartered in Jacou near Montpellier, specializes in proprietary long-acting injectable drug formulations designed to improve patient adherence across several therapeutic areas. Its portfolio already includes a schizophrenia treatment that Teva commercializes in the United States. The company employs roughly 140 people and generated €27.7 million in revenue in fiscal-year 2024. With the new capital, MedinCell plans to accelerate value-adding partnerships to launch additional programs and to upgrade its technology platform with next-generation injection technologies. Management intends to leverage these innovations to broaden the pipeline and reinforce the firm’s leadership in sustained-release injectables. The strategy focuses on both internal R&D and external collaborations to expand clinical and commercial reach.

Total raised

$122M

Funding rounds

5

Latest round

Equity

Latest activity

Mar 2026